Status:
NOT_YET_RECRUITING
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)
Conditions:
Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
Eligibility:
All Genders
18+ years
Brief Summary
PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic cou...
Detailed Description
Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' medical charts or electronic medical re...
Eligibility Criteria
Inclusion
- Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.
- Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.
- Availability of the baseline and follow-up annotations
Exclusion
- Established immunodeficiency conditions.
- Secondary CNS localizations of DLBCL
- Transformed DLBCL
Key Trial Info
Start Date :
April 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07147751
Start Date
April 1 2026
End Date
December 1 2029
Last Update
August 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo Pavia
Pavia, Italy, 27100
2
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Bellinzona, Switzerland, 6500